Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.

Franz M, Berndt A, Neri D, Galler K, Grün K, Porrmann C, Reinbothe F, Mall G, Schlattmann P, Renner A, Figulla HR, Jung C, Küthe F.

Int J Cardiol. 2013 Oct 15;168(6):5344-51. doi: 10.1016/j.ijcard.2013.08.005. Epub 2013 Aug 15.


[Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].

Yang YJ, Zhang X, Zhu WL, Huang Y.

Zhonghua Yi Xue Za Zhi. 2006 Jun 27;86(24):1693-6. Chinese.


De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Franz M, Matusiak-Brückner M, Richter P, Grün K, Ziffels B, Neri D, Maschek H, Schulz U, Pfeil A, Jung C, Figulla HR, Gummert J, Berndt A, Renner A.

J Mol Histol. 2014 Oct;45(5):519-32. doi: 10.1007/s10735-014-9573-4. Epub 2014 May 3.


Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.

Franz M, Grün K, Richter P, Brehm BR, Fritzenwanger M, Hekmat K, Neri D, Gummert J, Figulla HR, Kosmehl H, Berndt A, Renner A.

Histochem Cell Biol. 2010 Nov;134(5):503-17. doi: 10.1007/s00418-010-0750-6. Epub 2010 Oct 8.


Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy.

Rubiś P, Wiśniowska-Śmialek S, Wypasek E, Biernacka-Fijalkowska B, Rudnicka-Sosin L, Dziewiecka E, Faltyn P, Khachatryan L, Karabinowska A, Kozanecki A, Tomkiewicz-Pająk L, Podolec P.

Inflamm Res. 2016 Dec;65(12):941-949. Epub 2016 Aug 11.


Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

Gabler U, Berndt A, Kosmehl H, Mandel U, Zardi L, Müller S, Stelzner A, Katenkamp D.

Heart. 1996 Apr;75(4):358-62.


Cardiac extracellular matrix tenascin-C deposition during fibronectin degradation.

Ma S, Yang D, Li D, Tang B, Sun M, Yang Y.

Biochem Biophys Res Commun. 2011 Jun 3;409(2):321-7. doi: 10.1016/j.bbrc.2011.05.013. Epub 2011 May 8.


Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.

Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A; Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan.

Circ J. 2007 Mar;71(3):327-30.


Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.

Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, Yamada T, Imanaka-Yoshida K, Yoshida T, Ito M, Hiroe M.

J Card Fail. 2009 Dec;15(10):898-905. doi: 10.1016/j.cardfail.2009.06.443. Epub 2009 Aug 26.


Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.

Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B.

Clin Res Cardiol. 2006 May;95(5):261-9. Epub 2006 Apr 3.


Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG.

Circulation. 1998 May 5;97(17):1708-15.


Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Franz M, Grün K, Betge S, Rohm I, Ndongson-Dongmo B, Bauer R, Schulze PC, Lichtenauer M, Petersen I, Neri D, Berndt A, Jung C.

Oncotarget. 2016 Dec 6;7(49):81241-81254. doi: 10.18632/oncotarget.13220.


Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.

Fernandez-Garcia B, Eiró N, Marín L, González-Reyes S, González LO, Lamelas ML, Vizoso FJ.

Histopathology. 2014 Mar;64(4):512-22. doi: 10.1111/his.12300. Epub 2013 Nov 28.


Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.

Ziffels B, Ospel J, Grün K, Neri D, Pfeil A, Fritzenwanger M, Figulla HR, Jung C, Berndt A, Franz M.

Dis Markers. 2016;2016:3695454. doi: 10.1155/2016/3695454. Epub 2016 Aug 18.


Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1.

Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T.

Int J Cancer. 2003 May 20;105(1):53-60.


Serum levels of tenascin-C variants in congestive heart failure patients: comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy.

Franz M, Berndt A, Grün K, Kuethe F, Fritzenwanger M, Figulla HR, Jung C.

Clin Lab. 2014;60(6):1007-13.


Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression.

Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N.

Eur J Cancer. 2002 Dec;38(18):2362-70.


Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.

Ohtsuka T, Nishimura K, Kurata A, Ogimoto A, Okayama H, Higaki J.

J Card Fail. 2007 Nov;13(9):752-8.


Supplemental Content

Support Center